Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

Summary by Rutland Herald
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 21, 2026-

5 Articles

Seeking AlphaSeeking Alpha
Lean Right

FDA accepts Roche application for Gazyva/Gazyvaro in common lupus treatment

Roche’s Gazyva lupus FDA filing: B-cell anti-CD20 could be new SLE standard of care.

·United States
Read Full Article
The Manila TimesThe Manila Times
Lean Right

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus...

·Manila, Philippines (the)
Read Full Article
Rutland HeraldRutland Herald
+2 Reposted by 2 other sources
Center

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 21, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources lean Right
67% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Carroll County Mirror-Democrat broke the news in Mount Carroll, United States on Tuesday, April 21, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal